Intelligence · Patents
Patents expiring in 2044
Annual patent cliff calendar for 2044 — US pharmaceutical patents by expiration date.
- Patents
- 1,766
Quick answer
1,766 indexed pharmaceutical patents have expiration dates in 2044. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 12144812
Formulations of pyrimidine cyclohexyl glucocorticoid receptor modulators
granted -
US 12144869
Anti-ROR1 antibody conjugates, compositions comprising anti ROR1 antibody conjugates, and methods of making and using anti-ROR1 antibody conjugates
granted -
US 12145925
Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer
granted -
US 12145944
Imidazopyrimidines as EED inhibitors and the use thereof
granted -
US 12145941
Heterocyclic antiviral agents
granted -
US 12145943
Solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
granted -
US 12144802
Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug
granted -
US 12144809
Treatment of prostate cancer
granted -
US 12144801
Methods and compositions for treatment of epileptic disorders
granted -
US 12146004
Polymyxin compounds and uses thereof
granted -
US 12144788
Visual cycle modulators
granted -
US 12144828
Human Kynureninase enzymes and uses thereof
granted -
US 12144877
Graphene-based multifunctional cosmetic compositions
granted -
US 12152061
T-cell modulatory multimeric polypeptides and methods of use thereof
granted -
US 12151001
Optimized expression cassettes for gene therapy
granted -
US 12152028
Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
granted -
US 12152242
CRISPR therapy
granted -
US 12152262
PH20 polypeptide variants, formulations and uses thereof
granted -
US 12151998
Solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N′-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride and compositions, methods and kits related thereto
granted -
US 12152071
EGFL6 specific monoclonal antibodies and methods of their use
granted -
US 12151024
Manufacturing of bupivacaine multivesicular liposomes
granted -
US 12152038
Vasopressin receptor antagonists and products and methods related thereto
granted -
US 12152244
Selective antisense compounds and uses thereof
granted -
US 12150461
Nicotinamide adenine dinucleotide (NAD) compositions, methods of manufacturing thereof, and methods of use thereof
granted -
US 12152007
Substituted heterocycles as c-MYC targeting agents
granted -
US 12152067
Human antibodies to ebola virus glycoprotein
granted -
US 12150445
Method and composition for hypothermic storage of placental tissue
granted -
US 12152034
FGFR inhibitors and methods of making and using the same
granted -
US 12150957
Trace element compositions, methods of making and use
granted -
US 12152027
Heterocyclic compound
granted -
US 12150959
Chimeric antigen receptors with BCMA specificity and uses thereof
granted -
US 12152270
Neurotransmitter transport in probiotics
granted -
US 12150777
Treatment of depression
granted -
US 12150956
Trace element compositions, methods of making and use
granted -
US 12150998
Bicyclic peptide ligands specific for P-selectin
granted -
US 12151062
Compositions and devices to administer pharmaceutical compositions nasally
granted -
US 12150995
IRAK degraders and uses thereof
granted -
US 2024390317
COMBINATION TREATMENT AND/OR PREVENTION OF CARDIAC DISEASES IN NON-HUMAN MAMMALS COMPRISING ONE OR MORE SGLT-2 INHIBITORS AND PIMOBENDAN AND/OR TELMISARTAN
granted -
US 2024390332
Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more SGLT-2 inhibitors and telmisartan
granted -
US 2024390367
METHODS OF TREATING VITILIGO WITH UPADACITINIB
granted -
WO 2024242579
RÉGIMES DE TRAITEMENT DE LA MALADIE DE PARKINSON IDIOPATHIQUE PRÉCOCE
granted -
WO 2024243450
MÉTHODES DE TRAITEMENT UTILISANT DES CONJUGUÉS ANTICORPS-MÉDICAMENT ANTI-C-MET
granted -
US 12157762
Tethered interleukin-15 and interleukin-21
granted -
US 12156903
Use of ADAMTS13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome
granted -
US 12156940
Manufacturing of bupivacaine multivesicular liposomes
granted -
US 12156879
Combining BACE1 inhibitors with mGluR agonists for Alzheimer's disease therapy
granted -
US 12156897
Magnesium-containing oxytocin formulations and methods of use
granted -
US 12156893
Oral composition comprising lactic acid bacteria for regulating immune responses and methods related thereto
granted
Frequently asked questions
How many pharma patents expire in 2044?
1,766 published patents in our USPTO index have expiration dates falling in calendar year 2044.